Cargando…

Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study

With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Unterberger, Ursula, Lachmann, Ingolf, Voigtländer, Till, Pirker, Walter, Berghoff, Anna S., Flach, Katharina, Wagner, Uta, Geneste, Aline, Perret-Liaudet, Armand, Kovacs, Gabor G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151342/
https://www.ncbi.nlm.nih.gov/pubmed/25131945
http://dx.doi.org/10.5414/NP300796
_version_ 1782333013551480832
author Unterberger, Ursula
Lachmann, Ingolf
Voigtländer, Till
Pirker, Walter
Berghoff, Anna S.
Flach, Katharina
Wagner, Uta
Geneste, Aline
Perret-Liaudet, Armand
Kovacs, Gabor G.
author_facet Unterberger, Ursula
Lachmann, Ingolf
Voigtländer, Till
Pirker, Walter
Berghoff, Anna S.
Flach, Katharina
Wagner, Uta
Geneste, Aline
Perret-Liaudet, Armand
Kovacs, Gabor G.
author_sort Unterberger, Ursula
collection PubMed
description With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of β-sheet rich oligomers. We applied both tests in CSF from a series of neuropathologically confirmed α-synucleinopathy cases, including Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) (n = 7), as well as Alzheimer’s disease (n = 6), and control patients without neurodegenerative pathologies (n = 9). Disease-specific α-synuclein was detectable in the CSF in a subset of patients with α-synuclein pathology in the brain. When combined with the analysis of total α-synuclein, the bead-assay for disease-specific α-synuclein was highly specific for PDD/DLB. Detection of disease-associated α-synuclein combined with the total levels of α-synuclein is a promising tool for the in-vivo diagnosis of α-synucleinopathies, including PDD and LBD.
format Online
Article
Text
id pubmed-4151342
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dustri-Verlag Dr. Karl Feistle
record_format MEDLINE/PubMed
spelling pubmed-41513422014-09-18 Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study Unterberger, Ursula Lachmann, Ingolf Voigtländer, Till Pirker, Walter Berghoff, Anna S. Flach, Katharina Wagner, Uta Geneste, Aline Perret-Liaudet, Armand Kovacs, Gabor G. Clin Neuropathol Research Article With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of β-sheet rich oligomers. We applied both tests in CSF from a series of neuropathologically confirmed α-synucleinopathy cases, including Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) (n = 7), as well as Alzheimer’s disease (n = 6), and control patients without neurodegenerative pathologies (n = 9). Disease-specific α-synuclein was detectable in the CSF in a subset of patients with α-synuclein pathology in the brain. When combined with the analysis of total α-synuclein, the bead-assay for disease-specific α-synuclein was highly specific for PDD/DLB. Detection of disease-associated α-synuclein combined with the total levels of α-synuclein is a promising tool for the in-vivo diagnosis of α-synucleinopathies, including PDD and LBD. Dustri-Verlag Dr. Karl Feistle 2014 2014-08-18 /pmc/articles/PMC4151342/ /pubmed/25131945 http://dx.doi.org/10.5414/NP300796 Text en © Dustri-Verlag Dr. K. Feistle http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Unterberger, Ursula
Lachmann, Ingolf
Voigtländer, Till
Pirker, Walter
Berghoff, Anna S.
Flach, Katharina
Wagner, Uta
Geneste, Aline
Perret-Liaudet, Armand
Kovacs, Gabor G.
Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
title Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
title_full Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
title_fullStr Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
title_full_unstemmed Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
title_short Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
title_sort detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151342/
https://www.ncbi.nlm.nih.gov/pubmed/25131945
http://dx.doi.org/10.5414/NP300796
work_keys_str_mv AT unterbergerursula detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy
AT lachmanningolf detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy
AT voigtlandertill detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy
AT pirkerwalter detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy
AT berghoffannas detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy
AT flachkatharina detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy
AT wagneruta detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy
AT genestealine detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy
AT perretliaudetarmand detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy
AT kovacsgaborg detectionofdiseaseassociatedasynucleininthecerebrospinalfluidafeasibilitystudy